Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)

Abstract Background In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first‐line chemotherapy in advanced gastric cancer. Patients and Methods Patients with metastatic gastric or gastroesophageal junction adeno...

Full description

Bibliographic Details
Main Authors: Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Cancer Medicine
Subjects:
capecitabine
chemotherapy
cisplatin
gastric cancer
sorafenib
VEGF
Online Access:https://doi.org/10.1002/cam4.5536

Internet

https://doi.org/10.1002/cam4.5536

Similar Items